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Introduction:
SS is a common autoimmune rheumatic condition, associated with localised symptoms of ocular and mouth dryness as a consequence of decreased lacrimal and salivary secretion due to the lymphocyte infiltration of the exocrine glands (1, 2). The incidence of pSS varies among different populations and depends on the classification criteria used for diagnosis (3, 4) . A recent meta-analysis showed an incidence of 6.92 (95% CI 4.98 to 8.86) per 100 000 person-years and overall prevalence of 60.82 (95% CI 43.69 to 77.94) cases per 100 000 (5) .
The pathogenesis of dry eye symptoms associated with SS remains uncertain (6, 7) ; lacrimal gland infiltration with B and T lymphocytes and epithelial cells activation driven by cytotoxic T cells, together with increased apoptosis, and expression of Ro and La antibodies on the surface of apoptotic cells are considered to be the main pathogenic events associated with glandular destruction in SS (8) . More recently, it was found that abnormal apoptosis, cytokine and toll-like receptor (TLR) activation and perivascular lymphocytic infiltration are present in the glandular tissue even before the onset of clinical symptoms associated with SS (9) . In contrast, the systemic features of SS seem to be more associated with B cell activation, autoantibody production and polyclonal hypergammaglobulinaemia, which is likely to be linked to the increased risk of lymphoma observed in these patients (10, 11) .
Despite the recent efforts of ophthalmologists to define and classify the dry eye disease (12) , very few publications have critically reviewed the evidence for treatment recommendations (13) .
The ocular dryness is always associated with a localised inflammatory process and damage of the ocular surface, which is common to all underlying conditions (14) . Although often labelled as a benign feature of SS, the eye dryness can lead to decreased quality of life and potentially severe complications (15) . A recent study found no correlation between the perceived sicca symptoms and the tear secretion in pSS patients, despite good correlation with age and disease activity (16) . The incidence of dry eye is increased in the older population (17) and also after cataract and refractive surgery (18) . Symptoms of ocular dryness are reported with different frequency by patients with rheumatic conditions (19, 20) .
Methods:
We search PubMed (MEDLINE) and EMBASE electronic data bases from January 1994 to September 2014, aiming to identify reports about different therapies for dry ocular symptoms associated with SS, using the following MeSH terms: Sjogren's syndrome treatment, dry eye treatment, sicca syndrome and keratoconjunctivitis sicca treatment.
Using all these terms combined, we identified 458 articles. Only the articles in English, reporting on data about the effectiveness of treatment in SS were included in the review (n=163). We excluded case reports and animal model studies, and complemented the electronic search by a hand research of the references of the review articles related to this topic. Ultimately, 78 relevant articles were carefully reviewed.
Therapeutic strategies
The current therapeutic armamentarium comprises artificial tears, topical applications of immunosuppressant therapies, systemic immunosuppressant and immunomodulatory therapies, secretagogues and interventional treatments. We summarise below the main treatment options currently available for addressing of symptoms of dry eye associated with SS (Table 1) .
Topical treatments
It is currently recognised that the ocular dryness is associated with a local inflammatory process. The efficacy of topical antiinflamatories was tested in two randomised controlled trials (RCT), one prospective, open label, using diclofenac 0.1% drops (21) and one controlled, parallel group study, comparing diclofenac 0.1% with indomethacin 0.1 % eye drops (22) . Both studies showed improvement of the subjective symptoms in the NSAIDs treatment arms, which was not maintained at day 28 in the first study, and was associated with significant worsening of the corneal staining in the diclofenac group in the second study. It is currently accepted that topical NSAIDs should be used with caution in patients with SS (22) ( Table 1 ).
The use of topical corticosteroids was effective in one prospective trial of 53 SS patients, which used methylprednisolone, initially administered 4 times daily for the first two weeks, and tapered every 2 weeks. The treatment led to significantly improved tear break-up time (BUT) and Schirmer test results at the end of the treatment period and drug-free remission for a mean duration of 56.6 weeks and 20.8% recurrences. The clinical improvement was associated with an increased number of conjunctival goblet cells as assessed by impression cytology (23) .
The use of topical applications with artificial tears was associated with statistically significant changes in contrast sensitivity over a 4 hour period of instillation of a variety of artificial tears in patients with SS in a randomised controlled trial (RCT). It was also observed that the more muco-adhesive artificial tears demonstrated a significantly greater effect (24) .
Both artificial tears and punctal plugs relieved dry eye symptoms, repaired corneal lesions, enhanced tear film stability, and improved contrast sensitivity in patients with pSS (25) .
Instillations with 0.4% sodium hyaluronate were effective in achieving improvement in the rose bengal conjunctival stain starting from day 15 (p = 0.01) and for BUT and fluorescein corneal stain at day 90, but showed no improvement in the Schirmer's test, according to another RCT involving patients with primary (pSS) and secondary SS (26) .
Autologous serum (20%) topical applications were also associated with improvement in the Rose Bengal and fluorescein scores (p<0.01 and p<0.05, respectively) after 4 weeks (27) .
However, no significant change in BUT scores was observed, despite the improvement in the dryness sensation, as reported by 12 patients with pSS treated for 4 weeks. In another study, including 3 different groups of patients with ocular symptoms, autologous serum (concentration 100%) was associated with the best outcome in improving the sensation of dryness (p<0.01) and decrease of the corneal staining score in the SS group (p=0.041) after Several clinical trials investigated the efficacy of cyclosporine 0.05%, topical application, in patients with SS and dry eye symptoms (29) (30) (31) . In a 24 week RCT using two different doses, 0.5% and 1 %, there was evidence of improvement in several dry eye-related outcomes ( Cyclosporine topical applications improved both, the mean corneal fluorescein staining scores (p ≤ 0.001) and global physician assessment of dry eye status (in 72.7% SS patients) in a prospective study (31) .
Oral treatments:
Several oral treatments were used to assess their efficacy in controlling different symptoms associated with SS. Pilocarpine is a non-selective muscarinic acetylcholine receptor M3 agonist, known to stimulate the secretion of saliva and sweat, as established many years ago (34).
In a recent RCT, comparing the efficacy of pilocarpine 5 mg twice a day (n=29) with artificial tears (n=28) and inferior puncta occlusion (n=28), pilocarpine significantly improved the subjective global assessment of dry eyes compared with artificial tears (p<0.001) and inferior puncta occlusion (p<0.05). Furthermore, patients receiving oral pilocarpine also showed greater objective improvement, as measured by the Rose Bengal test (p<0.05), although the Schirmer test showed no differences between the treated groups (35) .
Another large RCT, placebo controlled, assessed the efficacy of pilocarpine 20-30 mg daily (dose adjustment study) vs. placebo in patients with SS. The pilocarpine group demonstrated both significant improvement in global assessment of dry eyes related symptoms (p 0.0001) and relief in 6 of 8 dry-related symptoms as assessed using a patient questionnaire (p≤0.04) at 12 weeks (30 mg/daily) (36).
In another RCT, pilocarpine 5 mg, four times daily, was effective in improving the symptoms associated with dry mouth and dry eye (61% vs, 31%, p<0.001 and 42% vs. 26%, p=0.009) in comparison with placebo (37) . The efficacy of cevimeline was confirmed in a prospective, double-blinded trial which followed up pSS patients for 4 weeks (20 mg t.d.s.) and in a 12 week RCT (30 mg t.d.s), which both showed statistically significant improvements in patient subjective global assessment of dry eyes and lacrimal flow rates, as measured by Schirmer's test (38, 39) .
Hydroxychloroquine (HCQ) has been used in SS and found beneficial in controlling the symptoms of oral dryness and joint pain associated with SS (40) .
The efficacy of HCQ in controlling symptoms of dry eye was confirmed in pSS patients in a prospective study where patients were assessed 3 months after stopping HCQ. However, a significant worsening was observed in, tear break up-time (TBUT) (P < 0.001), lissamine green (p < 0.01) and corneal fluorescein staining scores (p < 0.003). Improvement of subjective symptoms was also noted after 12 weeks treatment with HCQ (P < 0.007 and P < 0.003, respectively) (41) . A clinical improvement in the symptoms of ocular dryness was associated with decrease in the tear BAFF levels (41) . However, a recent RCT study showed no efficacy of HCQ in controlling the symptoms of dryness associated with SS after 24 weeks of treatment (42).
Methotrexate did not improve objective features of ocular dryness, despite being effective in improving the reported symptoms of dryness, as assessed by an open, one-year pilot study with weekly methotrexate (43) . A small open-label study with leflunomide 20 mg daily, including 15 patients with pSS with early and active disease, found no statistical significant difference in terms of perceived ocular dryness of objective improvement in the Schirmer test (44) . No significant improvement of the ocular dryness was reported in studies with azathioprine (45) or oral cyclosporine (46) , and the use of thalidomide was associated with prominent side-effects (47).
Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, was reported to be effective in increasing the secretion of both membrane-associated and secreted-type mucins through mucin production in the conjunctival goblet cells, and in the corneal epithelial cells (48) . This mucin secretagogue, used as ocular suspension was more effective than sodium hyaluronate at relieving the symptoms of ocular dryness and improving the corneal and conjunctival staining tests in a RCT in 188 patients with dry eye (49) . There are no studies available to assess its efficacy in patients with SS.
A large recent 6-week RCT, placebo controlled study, including 240 patients with SS and testing a Chinese traditional herbal medicine compound (granules) showed a significant improvement in the Schirmer test in both eyes, and also in the salivary flow, in the treatment arm compared with placebo (50).
The treatment of end-stage autoimmune dry eye associated disease with MICOF keratoprosthesis is considered to be one of the last resorts in the therapeutic armamentarium. Studies reported variable rates of success and additional treatment, comprising prophylactic autologous auricular cartilage implantation aiming to reinforce the anterior surface of recipient's cornea was needed to preserve the ocular integrity following corneal melting (51) . Despite the increasing experience with corneal transplants, there are no reports of this treatment being effective in the end-stage ocular disease associated with SS, suggesting that this condition is reasonably well controlled with conservative treatment. 
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A proposed algorithm:
Based on the available evidence from the literature data and the current recommendations for the management of dry eye symptoms (62), we propose a following algorithm (Figure 1) of ocular dryness treatment in patients with SS.
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In conclusion, the therapeutic armamentarium available for the treatment of ocular dryness associated with SS has expanded significantly in the last decade, as new biologic therapies targeting specific cells and molecules in patients with early disease have emerged. Apart from the biologic treatments, no systemic therapies are effective in SS. The dry eye treatment approach in SS differs from the treatment of other symptoms associated with SS, proving that patients benefit from an interdisciplinary approach and ophthalmological periodic review.
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